The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1577
ISSUE 1577
July 29, 2019
Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
July 29, 2019 (Issue: 1577)
The FDA has approved cyclosporine 0.09% ophthalmic
solution (Cequa – Sun) to increase tear production
in patients with keratoconjunctivitis sicca (dry eye
disease). Restasis, a 0.05% cyclosporine emulsion,
was approved in the US in 2003 for the same indication.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Cyclosporine 0.09% Solution (Cequa) for Dry Eye Disease
Article code: 1577c
Electronic, downloadable article - $45
Article code: 1577c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
